Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00580333 · ClinicalTrials.gov registry record · Phase 2
Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT00580333: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT00580333 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 51 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00580333, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
The purpose of this study is to find out what effect taking cisplatin in combination with bevacizumab before surgery and then standard chemotherapy plus bevacizumab after surgery will have on participants with Estrogen Receptor (ER) negative, Progesterone Receptor (PR) negative and Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer. Cisplatin is used to destroy cancer cells in many types of cancers, and has shown to be effective and have manageable side effects. Bevacizumab is an antibody, which is a protein that attacks a foreign substance in the body. Bevacizumab slows or stops cell growth in cancerous tumors by decreasing the blood supply to the tumors.
Interventions
- DRUG cisplatin
- DRUG cyclophosphamide
- DRUG bevacizumab
- DRUG doxorubicin
- DRUG paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2007-09 |
| Est. Completion | 2020-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00580333
The ClinicalTrials.gov registry entry for NCT00580333 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00580333 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00580333 about?
NCT00580333 is a clinical study titled "Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer". The purpose of this study is to find out what effect taking cisplatin in combination with bevacizumab before surgery and then standard chemotherapy plus bevacizumab after surgery will have on participants with Estrogen Receptor (ER) negative, Progesterone Receptor (PR) negative and Human Epidermal G...
What is the current status of trial NCT00580333?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2007-09. Estimated completion is 2020-06.
What interventions are being tested in trial NCT00580333?
The interventions under investigation include: cisplatin (DRUG), cyclophosphamide (DRUG), bevacizumab (DRUG), doxorubicin (DRUG), paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00580333?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.